Early Improvements in Cholestatic Pruritus With Long-Term Impact

Cholestatic Pruritus Efficacy

Early Improvements in Cholestatic Pruritus

Significant improvements in cholestatic pruritus from baseline were seen at the very first assessment (Week 3), with the full effect achieved by Week 18 and maintained through 1 year with once-daily LIVMARLI (P<0.0001).1,2

For patients who remained on treatment with LIVMARLI in the open-label extension (n=15), cholestatic pruritus responses compared with baseline were durable through nearly 4 years.1

Improvements in cholestatic pruritus over time graph Improvements in cholestatic pruritus over time graph
View Study Design and Select Baseline Characteristics

Study Design

ICONIC is the first pivotal study of an IBAT* inhibitor in Alagille syndrome to demonstrate significant improvement in cholestatic pruritus1†

The ICONIC study assessed efficacy and safety of treatment with LIVMARLI in children ≥1 year old with cholestatic pruritus associated with Alagille syndrome.1,2

This study consisted of an 18-week open-label treatment period; a 4-week randomized, double-blind, placebo-controlled drug-withdrawal period; a subsequent 26-week open-label treatment period; and a long-term open-label extension period.1,2

Cholestatic pruritus responses to LIVMARLI were assessed through approximately 4 years.1

Cholestatic pruritus was assessed at baseline using the Itch Reported Outcome (ItchRO) scale. The ItchRO score is a 0–4 scale, where 0 is none and 4 is very severe.1 This scale takes itch-related symptoms into consideration, including patients’ skin damage, sleep, and irritability.1,3,4

  • Participants’ baseline scores were calculated as the average of the daily ItchRO scores over the 2 consecutive weeks during the screening period1


All Participants (N=31)
Mean age at baseline visit, years (SD)5.4 (4.2)
Sex, n (%)
Female12 (39)
Male19 (61)
Genotyped mutation within JAG1, n (%)31 (100)
History of receiving treatment for pruritus, n (%)
Any medication29 (94)
Ursodeoxycholic acid25 (81)
Rifampicin23 (74)
Naltrexone1 (3)
Sertraline1 (3)
Trial parameter, mean (SD)
ItchRO(Obs) weekly morning 
average severity score
2.9 (0.5)
CSS score3.3 (0.9)
sBA, µmol/L283 (211)

*IBAT=ileal bile acid transporter.

Mean difference –1.4 points [95% CI, –2.1, –0.8].1

Included a 6-week dose escalation period for all participants during the first 6 weeks of the open-label treatment period and for participants who received placebo during the RWD.

§Twice per day dosing was allowed after Week 100. The approved dosage of LIVMARLI is 380 mcg/kg once daily.

Average ItchRO(Obs) scores are based on the 7 days prior to baseline visit.

FSV supplements were available as SOC throughout the study. No changes beyond SOC in supplementation occurred during the study.1

Safety, tolerability, and pharmacokinetics of LIVMARLI in patients aged 3 months to 1 year were evaluated in RISE, a 13-week, open-label, phase 2 study (N=8). Participants received LIVMARLI 380 μg/kg once daily, in addition to standard of care.2,5

CSS=Clinician Scratch Scale; FSV=fat-soluble vitamin; ItchRO=Itch Reported Outcome; JAG1=jagged canonical Notch ligand 1; RWD=randomized withdrawal period; sBA=serum bile acid; SD=standard deviation; SOC=standard of care.

References: 1. Gonzales E, Hardikar W, Stormon M, et al. Efficacy and safety of maralixibat treatment in patients with Alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study. Lancet. 2021;398(10311):1581-1592. doi:10.1016/S0140-6736(21)01256-3 2. LIVMARLI® (maralixibat) oral solution. Prescribing Information. Mirum Pharmaceuticals, Inc. 3. Kamath BM, Abetz-Webb L, Kennedy C, et al. Development of a novel tool to assess the impact of itching in pediatric cholestasis. Patient. 2018;11(1):69-82. doi:10.1007/s40271-017-0266-4 4. Kamath BM, Spino C, McLain R, et al. Unraveling the relationship between itching, scratch scales, and biomarkers in children with Alagille syndrome. Hepatol Commun. 2020;4(7):1012-1018. doi:10.1002/hep4.1522 5. Gonzales E, Jankowska I, Horslen S, et al. Safety and tolerability characterization of maralixibat in infants with ALGS from 2 months of age: interim results from the RISE study. Poster presented at: American Association for the Study of Liver Diseases: The Liver Meeting; November 4-8, 2022; Washington, DC.

Pie chart displaying the percentage of patients who experienced clinically meaningful improvements in cholestatic pruritus compared with baseline

During the first year of treatment, 84% (n=26/31) of patients with Alagille syndrome experienced clinically meaningful improvements in cholestatic pruritus compared with baseline with once-daily LIVMARLI.1

  • “Clinically meaningful” was defined as ≥1-point ItchRO(Obs) improvement vs baseline1

At 1 year, improvements in cholestatic pruritus were correlated with decreases in serum bile acid (sBA) (r=0.47).3


During the first year, patients receiving LIVMARLI in the pivotal ICONIC study had an increasing proportion of days with minimal to no cholestatic pruritus.4

  • In patients who remained on LIVMARLI (n=21) during the open-label extension (beyond 48 weeks), the median proportion of days with minimal to no cholestatic pruritus was 95%

*Cholestatic pruritus was assessed each day, in the morning and evening, using the Itch Reported Outcome (ItchRO) scale—a validated tool designed to assess the impact of cholestatic pruritus in people with cholestatic liver disease, including Alagille syndrome. The ItchRO score is a 0–4 scale, where 0 is none, 1 is mild, 2 is moderate, 3 is severe, and 4 is very severe. Changes in ItchRO score of 1.0 or more have been shown to be clinically meaningful. ItchRO(Obs) was completed by caregivers and was the basis for the key pruritus endpoint. The patient-rated ItchRO (ItchRO[Pt]) was completed independently by participants aged 9 years or older and with caregiver assistance for participants aged 5 to 8 years.1

Change from baseline, P<0.0001.

Included an initial 6-week dose escalation for participants previously receiving placebo.

§Based on mean daily morning ItchRO(Obs) scores in patients who remained on LIVMARLI through 4 years.4

Liver Survival

Long-Term Liver Impact

In a post hoc analysis, patients with Alagille syndrome who were treated with LIVMARLI in 3 long-term clinical trials were followed to identify predictors of long-term, transplant-free survival.5

In the post hoc analysis, 93% of patients who achieved a >1-point reduction in ItchRO(Obs) (n=46) remained transplant free 6 years after starting LIVMARLI.5,6

57% of patients who had ≤1-point reduction in ItchRO(Obs) (n=30) remained transplant free 6 years after starting LIVMARLI.5,6
Long-Term Liver Impact Long-Term Liver Impact
View Study Design

In a post hoc analysis, patients with Alagille syndrome who were treated with LIVMARLI in 3 long-term clinical trials (n=76) were followed to identify predictors of long-term, transplant-free survival.1

  • Transplant-free survival was defined as time to liver transplant or death1
  • Median follow-up was 5.1 years (range: 1.0 year to 7.3 years)2
  • This analysis included patients aged 14 months to 17.25 years, with median serum bile acids (sBA) 180 μmol/L (IQR, 78 to 361) and median ItchRO(Obs) score 2.7 (IQR, 2.1 to 3.1) at baseline1
  • Patients (n=76) with moderate-to-severe cholestatic pruritus who were on LIVMARLI 48 weeks from the first dose and had lab results at 48 weeks were included in this analysis1

References: 1. Sokol RJ, Gonzales EM, Kamath BM, et al. Predictors of 6-year event-free survival in Alagille syndrome patients treated with maralixibat, an ileal bile acid transporter inhibitor. Hepatology. Published June 7, 2023. 2. Sokol J, Gonzales E, Kamath BM, et al. Predictors of 6-year event-free survival in patients with Alagille syndrome treated with maralixibat, an IBAT inhibitor. Paper presented at: European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN): Annual Meeting; June 22-25, 2022; Copenhagen, Denmark.

Info About

Cholestatic pruritus was assessed using the Itch Reported Outcome (ItchRO[Obs]) tool. The ItchRO score is a 0–4 scale, where 0 is none and 4 is very severe.7

Safety First!

LIVMARLI has a well-characterized safety and tolerability profile for cholestatic pruritus in patients with Alagille syndrome.8,9

See the Safety Profile

Encourage patients to download the Itch✓ app to help them track symptom patterns over time and generate customized reports to share at appointments.

Check Out the Itch✓ App

Mirum Access Plus assists both you and your patients at every turn, helping you navigate the payer approval process—and beyond—with ease.

Learn More About
Mirum Access Plus
Collapse icon

Important Safety Information

Warnings and Precautions

Liver Test Abnormalities: Patients enrolled in clinical trials had abnormal liver tests at baseline. In the main clinical trial, treatment-emergent elevations or worsening of liver tests (ALT, AST or T/DB) relative to baseline were observed. Obtain baseline liver tests and monitor during treatment. Dose reduction or treatment interruption may be considered if abnormalities occur in the absence of other causes. For persistent or recurrent liver test abnormalities, consider treatment discontinuation. Discontinue permanently if a patient progresses to portal hypertension or experiences a hepatic decompensation event.

GI Adverse Reactions: Diarrhea, abdominal pain and vomiting were reported as the most common adverse reactions. If diarrhea, abdominal pain and/or vomiting occur and no other etiologies are found, consider reducing the dose or interrupting LIVMARLI. For diarrhea or vomiting, monitor for dehydration and treat promptly. Consider interrupting LIVMARLI dosing if a patient experiences persistent diarrhea or has diarrhea with accompanying signs and symptoms such as bloody stool, vomiting, dehydration requiring treatment, or fever. Restart LIVMARLI at 190 mcg/kg/day when diarrhea, abdominal pain or vomiting resolve, and increase the dose as tolerated. If they recur upon re-challenge, consider stopping LIVMARLI treatment.

Fat-Soluble Vitamin Deficiency: ALGS patients can have fat-soluble vitamin (FSV) deficiency (vitamins A, D, E, and K) at baseline, and LIVMARLI may affect absorption of FSV. In the main clinical trial, treatment emergent FSV deficiency was reported in 3 (10%) patients during 48 weeks of treatment. Obtain baseline serum levels and monitor during treatment, along with any clinical manifestations. Supplement if deficiency is observed. Consider discontinuing LIVMARLI if FSV deficiency persists or worsens despite adequate FSV supplementation.

Adverse Reactions

The most common adverse reactions (≥5%) are diarrhea, abdominal pain, vomiting, fat-soluble vitamin deficiency, liver test abnormalities, gastrointestinal bleeding and bone fractures.

Drug Interactions

Administer bile acid binding resins at least 4 hours before or 4 hours after administration of LIVMARLI.

A decrease in the absorption of OATP2B1 substrates (eg, statins) due to OATP2B1 inhibition by LIVMARLI in the GI tract cannot be ruled out. Consider monitoring the drug effects of OATP2B1 substrates as needed.

Dosing Information

LIVMARLI should be taken 30 minutes before a meal in the morning. The provided oral dosing dispenser must be used to accurately measure the dose. Any remaining LIVMARLI should be discarded 100 days after first opening the bottle.

Please see full Prescribing Information for LIVMARLI.